Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to...

by Woodworth, Thasia G, Furst, Daniel E
Published 2014

The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation

by Townes, Shatara V, Furst, Daniel E, Thenkondar, Anuradha
Published 2012

Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement

by Sullivan, Keith M., Shah, Ankoor, Sarantopoulos, Stefanie, Furst, Daniel E.
Published 2016

Clinical trials in systemic sclerosis: lessons learned and outcomes

by Matucci-Cerinic, Marco, Steen, Virginia D, Furst, Daniel E, Seibold, James R
Published 2007

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis

by Nurmohamed, Michael, Bao, Yanjun, Signorovitch, James, Trahey, Alex, Mulani, Parvez, Furst, Daniel E
Published 2015

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis

by Fleischmann, Roy, Weinblatt, Michael E., Schiff, Michael, Khanna, Dinesh, Maldonado, Michael A., Nadkarni, Anagha, Furst, Daniel E.
Published 2016

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials

by Combe, Bernard, Furst, Daniel E., Keystone, Edward C., van der Heijde, Désirée, Luijtens, Kristel, Ionescu, Lucian, Goel, Niti, Emery, Paul
Published 2016

Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiologi...

by Christensen, Anton Wulf, Tarp, Simon, Furst, Daniel E., Døssing, Anna, Amris, Kirstine, Bliddal, Henning, Taylor, Peter C., Christensen, Robin
Published 2015

Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project

by Amarilyo, Gil, Furst, Daniel E., Woo, Jennifer M. P., Li, Wen, Bliddal, Henning, Christensen, Robin, Tarp, Simon
Published 2016

Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol

by Dossing, Anna, Tarp, Simon, Furst, Daniel E, Gluud, Christian, Beyene, Joseph, Hansen, Bjarke B, Bliddal, Henning, Christensen, Robin
Published 2014

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

by van Vollenhoven, Ronald F, Emery, Paul, Bingham, Clifton O, Keystone, Edward C, Fleischmann, Roy M, Furst, Daniel E, Tyson, Nicola, Collinson, Neil, Lehane, Patricia B
Published 2013

Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predi...

by Kay, Jonathan, Morgacheva, Olga, Messing, Susan P, Kremer, Joel M, Greenberg, Jeffrey D, Reed, George W, Gravallese, Ellen M, Furst, Daniel E
Published 2014

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a...

by Emery, Paul, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, Furst, Daniel E, Barré, Emilie, Karyekar, Chetan S, Wong, Dennis A, Huizinga, Tom W J
Published 2015

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed

by Denton, Christopher P, Avouac, Jerome, Behrens, Frank, Furst, Daniel E, Foeldvari, Ivan, Humbert, Marc, Huscher, Doerte, Kowal-Bielecka, Otylia, Matucci-Cerinic, Marco, Nash, Peter, Opitz, Christian F, Pittrow, David, Rubin, Lewis J, Seibold, James R, Distler, Oliver
Published 2011

Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

by Fleming, Jo N., Nash, Richard A., McLeod, D. O., Fiorentino, David F., Shulman, Howard M., Connolly, M. Kari, Molitor, Jerry A., Henstorf, Gretchen, Lafyatis, Robert, Pritchard, David K., Adams, Lawrence D., Furst, Daniel E., Schwartz, Stephen M.
Published 2008

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis

by Peterfy, Charles, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, DiCarlo, Julie C, Furst, Daniel E, Huizinga, Tom W J, Wong, Dennis A, Conaghan, Philip G, Emery, Paul
Published 2016

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sc...

by Khanna, Dinesh, Nagaraja, Vivek, Tseng, Chi-hong, Abtin, Fereidoun, Suh, Robert, Kim, Grace, Wells, Athol, Furst, Daniel E., Clements, Philip J., Roth, Michael D., Tashkin, Donald P., Goldin, Jonathan
Published 2015

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set

by Bykerk, Vivian P, Bingham, Clifton O, Choy, Ernest H, Lin, Daming, Alten, Rieke, Christensen, Robin, Furst, Daniel E, Hewlett, Sarah, Leong, Amye, March, Lyn, Woodworth, Thasia, Boire, Gilles, Haraoui, Boulos, Hitchon, Carol, Jamal, Shahin, Keystone, Edward C, Pope, Janet, Tin, Diane, Thorne, J Carter, Bartlett, Susan J
Published 2016

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised...

by Tashkin, Donald P, Roth, Michael D, Clements, Philip J, Furst, Daniel E, Khanna, Dinesh, Kleerup, Eric C, Goldin, Jonathan, Arriola, Edgar, Volkmann, Elizabeth R, Kafaja, Suzanne, Silver, Richard, Steen, Virginia, Strange, Charlie, Wise, Robert, Wigley, Fredrick, Mayes, Maureen, Riley, David J, Hussain, Sabiha, Assassi, Shervin, Hsu, Vivien M, Patel, Bela, Phillips, Kristine, Martinez, Fernando, Golden, Jeffrey, Connolly, M Kari, Varga, John, Dematte, Jane, Hinchcliff, Monique, Fischer, Aryeh, Swigris, Jeffrey, Meehan, Richard, Theodore, Arthur, Simms, Robert, Volkov, Suncica, Schraufnagel, Dean E, Scholand, Mary Beth, Frech, Tracy, Molitor, Jerry A, Highland, Kristin, Read, Charles A, Fritzler, Marvin J, Kim, Grace Hyun J, Tseng, Chi-Hong, Elashoff, Robert M
Published 2016

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients

by Wu, Minghua, Assassi, Shervin, Salazar, Gloria A., Pedroza, Claudia, Gorlova, Olga Y., Chen, Wei V., Charles, Julio, Taing, Miranda L., Liao, Kelley, Wigley, Fredrick M., Hummers, Laura K., Shah, Ami A., Hinchcliff, Monique, Khanna, Dinesh, Schiopu, Elena, Phillips, Kristine, Furst, Daniel E., Steen, Virginia, Baron, Murray, Hudson, Marie, Zhou, Xiaodong, Pope, Janet, Jones, Niall, Docherty, Peter, Khalidi, Nader A., Robinson, David, Simms, Robert W., Silver, Richard M., Frech, Tracy M., Fessler, Barri J., Fritzler, Marvin J., Molitor, Jerry A., Segal, Barbara M., Movahedian, Malahat, Martín, Javier, Varga, John, Mayes, Maureen D.
Published 2016